antibody drug conjugates

News

Gilead strikes again, penning $5bn deal to buy Tubulis

Gilead has signed its third acquisition deal since the start of the year, agreeing to buy ADC specialist Tubulis for $3.15bn upfront.

News

AbbVie bags first approval for cancer ADC Emrelis

AbbVie has claimed its first global regulatory approval, from the FDA, for its C-met-targeting lung cancer ADC Emrelis.

News

US District Court for the Western District of Washington at Seattle

AbbVie sues Genmab, claiming trade secrets theft

A multibillion-dollar partnership between AbbVie and Genmab risks being soured by a lawsuit claiming misappropriation of trade secrets.

News

Taiho snaps up ADC partner Araris for up to $1.14bn

Taiho has reached a deal to buy Swiss biotech Araris, around 18 months after they started collaborating on antibody-drug conjugates for cancer.

News

MSD, Daiichi Sankyo lung cancer ADC starts phase 3

One of three antibody-drug conjugates licensed by MSD for $4 billion upfront last year has started phase 3 testing in a form of lung cancer.

News

Ipsen forges another ADC alliance, this time with Foreseen

Ipsen’s big partnering push to expand its pipeline shows no signs of abating, with the latest deal a $1 billion wager on an antibody-drug conjugate (ADC) for cancer developed by Foreseen Bi

Gilead strikes again, penning $5bn deal to buy Tubulis

AbbVie bags first approval for cancer ADC Emrelis

AbbVie sues Genmab, claiming trade secrets theft

Taiho snaps up ADC partner Araris for up to $1.14bn

MSD, Daiichi Sankyo lung cancer ADC starts phase 3

Ipsen forges another ADC alliance, this time with Foreseen

EMA advisors say CSL's Tavneos should be pulled from sale

Discover a new era of healthcare panel engagement: Grounded ...

antibody drug conjugates

Editor's Picks